Translational neuroimaging: positron emission tomography studies of monoamine oxidase
Abstract
Positron emission tomography (PET) using radiotracers with high molecular specificity is an important scientific tool in studies of monoamine oxidase (MAO), an important enzyme in the regulation of the neurotransmitters dopamine, norepinephrine, and serotonin as well as the dietary amine, tyramine. MAO occurs in two different subtypes, MAO A and MAO B, which have different substrate and inhibitor specificity and which are different gene products. The highly variable subtype distribution with different species makes human studies of special value. MAO A and B can be imaged in the human brain and certain peripheral organs using PET and carbon-11 (half-life 20.4 minutes) labeled mechanism-based irreversible inhibitors, clorgyline and L -deprenyl, respectively. In this article we introduce MAO and describe the development of these radiotracers and their translation from preclinical studies to the investigation of variables affecting MAO in the human brain and peripheral organs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MAO subtypes are expressed by both neurons and reactive astrocytes.
“MAO subtypes are expressed by both neurons (MAOA, especially in basal ganglia) and reactive astrocytes (mainly MAOB) (Fowler et al., 2005; Ben Haim et al., 2015).”
From Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum (2020) · cites this paper as Fowler et al., 2005
Cites
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058 · see citing works
Monoamine oxidase and cigarette smoking
Fowler, J. S., Logan, J., Wang, G.-J., & Volkow, N. D. (2003) · NeuroToxicology · doi:10.1016/s0161-813x(02)00109-2 · Cited by 251 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · see citing works
“The enzyme MAO-B exists on the outer mitochondrial membrane, occurring predominantly in astrocytes (9,10).”
BackgroundRodriguez-Vieitez, E., Saint-Aubert, L., Carter, S. F., Almkvist, O., Farid, K. A., Schöll, M., Chiotis, K., Thordardottir, S., Graff, C., Wall, A., et al. (2016) · Brain : a journal of neurology · doi:10.1093/brain/awv404 · Cited by 285 · see citing works
Brain Monoamine Oxidase A Activity Predicts Trait Aggression
Alia-Klein, N., Goldstein, R., Kriplani, A., Logan, J., Tomasi, D., Williams, B. M., Telang, F., Shumay, E., Biegon, A., Craig, I., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0925-08.2008 · Cited by 240 · see citing works
“Although both subtypes are highest in the thalamus, MAO A is higher in cortical regions than MAO B (Fowler et al., 2005).”
BackgroundSelf-citationGulyás, B. Z., Pavlova, E. L., Kása, P., Gulya, K., Bakota, L., Várszegi, S., Keller, É., Horváth, M. C., Nag, S., Hermecz, I., et al. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.013 · Cited by 203 · see citing works
“Since the original labeling of L-deprenyl as a prospective PET radioligand (Fowler et al., 1987), [11C]-L-deprenyl has been used successfully as a PET radioligand in normal subjects (Lammertsma et al., 1991; Hirvonen et al., 2009) and neurological patients.”
InfluentialNarayanaswami, V., Dahl, K., Bernard‐Gauthier, V., Josephson, L., Cumming, P. D., & Vasdev, N. (2018) · Molecular Imaging · doi:10.1177/1536012118792317 · Cited by 215 · see citing works
“Several radiotracers have been developed for MAO-B PET imaging, yet the majority of clinical research studies have been led using the propargyl compound L-[(11)C]deprenyl to evaluate MAO-B in human neuropsychiatric studies.(54,108,109) In the past Table 1.”
BackgroundNeuroimaging for drug addiction and related behaviors
Parvaz, M. A., Alia-Klein, N., Woicik, P. A., Volkow, N. D., & Goldstein, R. Z. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.055 · Cited by 151 · see citing works
“For example, PET studies have assessed the effects of cigarette smoke on the concentration of monoamine oxidases (MAO A and MAO B) in the human brain and body (Fowler et al. , 2005 ).”
Self-citationReactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer’s disease
Kumar, A., Fontana, I. C., & Nordberg, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15565 · Cited by 150 · see citing works
“PET- imaging is a powerful in vivo technique that uses selective and specific PET- tracers to monitor specific proteins, their location and density as well as metabolic processes in the body (Fowler et al., 2005).”
BackgroundVermeiren, C., Motte, P., Viot, D., Mairet‐Coello, G., Courade, J., Citron, M., Mercier, J., Hannestad, J., & Gillard, M. (2018) · Movement Disorders · doi:10.1002/mds.27271 · Cited by 143 · see citing works
“The increased binding with age could be driven by AV-1451’s high affinity for MAOB, because the MAO-B expression level, for example, in the globus pallidus, increases with age.(20,28,29) MAO-A and -B protein levels were also reported to change in diseases such as AD and Huntington’s disease,(30-33) adding complexity t…”
BackgroundSchöll, M., Carter, S. F., Westman, E., Rodriguez‐Vieitez, E., Almkvist, O., Þórðardóttir, S., Wall, A. E., Graff, C., Långström, B., & Nordberg, A. K. (2015) · Scientific Reports · doi:10.1038/srep16404 · Cited by 146 · see citing works
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum
Bevan-Jones, W. R., Cope, T. E., Jones, P. S., Kaalund, S. S., Passamonti, L., Allinson, K., Green, O., Hong, Y. T., Fryer, T. D., Arnold, R., et al. (2020) · Brain · doi:10.1093/brain/awaa033 · Cited by 124 · see citing works
“Although 18F-AV-1451 has weak affinity for both types of MAO (Drake et al., 2019), selective blockade of MAOA and MAOB leads to only minor changes in the estimated cortical binding from PET in nonhuman primates (Drake et al., 2019), while clinical treatment with MAO inhibitors does not significantly change estimated 1…”
BackgroundTarget site occupancy: emerging generalizations from clinical and preclinical studies.
Grimwood, S., & Hartig, P. (2009) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2009.03.002 · Cited by 124 · see citing works
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121 · see citing works
“Moreover, it is unclear the degree to which the [(11)C]DED signal represents reactive astrocytosis, since MAO-B is also found within serotonergic neurons and non-reactive astrocytes [108,109].”
BackgroundShumay, E., Logan, J., Volkow, N. D., & Fowler, J. S. (2012) · Epigenetics · doi:10.4161/epi.21976 · Cited by 120 · see citing works
Self-citationSerotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113 · see citing works
Molecular aspects of monoamine oxidase B.
Ramsay, R. (2016) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.005 · Cited by 88 · see citing works
“For the best AC C T pharmacological effect, MAO B must be more than 90% inhibited (Fowler et al., 2005).”
Monoamine oxidases in major depressive disorder and alcoholism.
Duncan, J. W., Johnson, S., & Ou, X.-M. (2012) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2012.v6.3.112 · Cited by 84 · see citing works
“many xenobiotics by controlling their availability and physiological activity (2).”
BackgroundCerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75 · see citing works
“This molecule is an irreversible MAO-B inhibitor with high affinity and specificity for this enzyme, predominantly expressed on the outer mitochondrial membrane of astrocytes [39].”
BackgroundAbourbeh, G., Dissoki, S., Jacobson, O., Litchi, A., Ben-Daniel, R., Laki, D., Levitzki, A., & Mishani, E. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.10.012 · Cited by 71 · see citing works
“[82,85] have employed this mechanistic tool to image MAO A and MAO B in the human brain, as well as to assess the binding specificity for MAO isoforms in peripheral organs in human subjects.”
MethodRadiosynthesis of [11C]SL25.1188 via [11C]CO2 fixation for imaging monoamine oxidase B
Vasdev, N., Sadovski, O., Garcia, A., Dollé, F., Meyer, J., Houle, S., & Wilson, A. (2011) · doi:10.1002/jlcr.1908 · Cited by 68
Monoamine oxidase: radiotracer chemistry and human studies.
Fowler, J., Logan, J., Shumay, E., Alia-Klein, N., Wang, G.-J., & Volkow, N. (2015) · Journal of labelled compounds & radiopharmaceuticals · doi:10.1002/jlcr.3247 · Cited by 67 · see citing works
“Seeking an F-18 labeled MAO-B radiotracer that was easier to synthesize, Mukherjee reported the radiosynthesis of N-(6-(18)F-fluorohexyl)-N-methylpropargylamine (11).”
BackgroundSelf-citationKrysiak, J. M., Kreuzer, J., Macheroux, P., Hermetter, A., Sieber, S. A., & Breinbauer, R. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201955 · Cited by 76 · see citing works
Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
Vilaplana, E., Rodriguez‐Vieitez, E., Ferreira, D., Montal, V., Almkvist, O., Wall, A. E., Lleó, A., Westman, E., Graff, C., Fortea, J., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009405 · Cited by 68 · see citing works
Choo, I. H., Carter, S. F., Schöll, M., & Nordberg, A. K. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2859-7 · Cited by 62 · see citing works
“predominantly in astrocytes [3-5].”
Esteban, G., Allan, J., Samadi, A., Mattevi, A., Unzeta, M., Marco-Contelles, J., Binda, C., & Ramsay, R. (2014) · Biochimica et Biophysica Acta · doi:10.1016/j.bbapap.2014.03.006 · Cited by 57 · see citing works
“Clorgyline (MAO A-selective) and L-deprenyl (MAO B-selective) are extensively used in vivo [45,46], so this information will be a useful background for future in vivo profiling of the new compounds.”
BackgroundThe emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 51 · see citing works
“Astrocytosis can be uniquely measured through PET and the 11 C-deuterium-L-deprenyl ligand ( 11 C-DED), which is an irreversible inhibitor of the MAO-B enzyme, over-expressed during astrocyte activation 150 .”
BackgroundInflaming the Brain: CRPS a model disease to understand Neuroimmune interactions in Chronic Pain
Linnman, C., Becerra, L., & Borsook, D. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9422-8 · Cited by 47 · see citing works
“The enzyme MAO-B exists on the outer mitochondrial membrane, occurring predominantly in astrocytes (Fowler et al. 2005).”
Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque
Holland, J. P., Liang, S. H., Rotstein, B. H., Collier, T. L., Stephenson, N. A., Greguric, I. D., & Vasdev, N. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3158 · Cited by 43 · see citing works
Modeling of PET data in CNS drug discovery and development
Varnäs, K., Varrone, A., & Farde, L. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9320-6 · Cited by 44 · see citing works
Baler, R., Volkow, N. D., Fowler, J. S., & Benveniste, H. (2008) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0819 · Cited by 39 · see citing works
Self-citationEdison, P., & Brooks, D. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179929 · Cited by 62 · see citing works
Development of new radiopharmaceuticals for imaging monoamine oxidase B.
Vasdev, N., Sadovski, O., Moran, M. D., Parkes, J., Meyer, J., Houle, S., & Wilson, A. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.03.003 · Cited by 38 · see citing works
Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrumPreprint
Bevan-Jones, W. R., Cope, T., Jones, P. S., Passamonti, L., Hong, Y. T., Fryer, T., Arnold, R., Coles, J., Aigbirhio, F., Larner, A., et al. (2019) · bioRxiv · doi:10.1101/525642 · Cited by 30 · see citing works
Carollo, A., Cataldo, I., Fong, S., Corazza, O., & Esposito, G. (2022) · Addiction Neuroscience · doi:10.1016/j.addicn.2022.100048 · Cited by 26 · see citing works
Naoi, M., Maruyama, W., & Shamoto‐Nagai, M. (2018) · Journal of neural transmission · doi:10.1007/s00702-017-1832-6 · Cited by 28 · see citing works
Catecholamine and Indolamine Pathway: A Case–Control Study in Fibromyalgia
Rus, A., Molina, F., del Moral, M. L., Ramírez-Expósito, M., & Martínez-Martos, J. (2018) · Biological Research for Nursing · doi:10.1177/1099800418787672 · Cited by 27 · see citing works
Monoamine oxidase A and B substrates: probing the pathway for drug development.
Chajkowski-Scarry, S., & Rimoldi, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.23 · Cited by 27 · see citing works
Integrating PET with behavioral neuroscience using RatCAP tomography
Schulz, D., & Vaska, P. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.052 · Cited by 27 · see citing works
“…to assess glucose metabolism, receptor occupancy, and availability of transporters and enzymes in humans and animals (Fowler and Wolf , 1986 ; Dewey et al. , 1993 ; Kornblum et al. , 2000 ; Laruelle , 2000 ; Harada et al. , 2004 ; Fowler et al. , 2005 ; Logan et al. , 2007 ; Itoh et al. , 2009 ).”
BackgroundWang, J., & Edmondson, D. E. (2011) · Biochemistry · doi:10.1021/bi101722b · Cited by 26 · see citing works
“The known age-related increases in expression of Monoamine Oxidase B (MAO B)1 in neuronal tissue (1) and Monoamine Oxidase A (MAO A) in heart (2) have been implicated in neurological (3) and cardiovascular disorders (4).”
BackgroundZukotynski, K., Kuo, P. H., Mikulis, D. J., Rosa‐Neto, P., Strafella, A. P., Subramaniam, R. M., & Black, S. E. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19822 · Cited by 30 · see citing works
Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
Rodriguez‐Vieitez, E., & Nordberg, A. K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7704-8_16 · Cited by 23 · see citing works
Tago, T., Toyohara, J., Sengoku, R., Murayama, S., & Ishii, K. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002564 · Cited by 23
Bottlaender, M., Valette, H., Delforge, J., Saba, W., Guenther, I., Curet, O., George, P., Dollé, F., & Grégoire, M. (2010) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1038/jcbfm.2009.242 · Cited by 22 · see citing works
Gealageas, R., Devineau, A., So, P. P. L., Kim, C., Surendradoss, J., Buchwalder, C., Heller, M., Goebeler, V., Dullaghan, E., Grierson, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01588 · Cited by 20 · see citing works
Hicks, J., Sadovski, O., Parkes, J., Houle, S., Hay, B., Carter, R. L., Wilson, A., & Vasdev, N. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.11.048 · Cited by 20 · see citing works
Tegler, G., Estrada, S., Hall, H., Wanhainen, A., Björck, M., Sörensen, J., & Antoni, G. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.894157 · Cited by 18 · see citing works
“L-[(11)C]Di-deuteriumdeprenyl (DED) is an irreversible inhibitor of monoamine oxidase type B (MAO-B) with high affinity and specificity (32,33).”
BackgroundFluorescent Peptide-PNA Chimeras for Imaging Monoamine Oxidase A mRNA in Neuronal Cells
Sethi, D., Chen, C.-P., Jing, R.-Y., Thakur, M., & Wickstrom, E. (2012) · Bioconjugate chemistry · doi:10.1021/bc2004507 · Cited by 18 · see citing works
11C- and 18F-Radiotracers for In Vivo Imaging of the Dopamine System: Past, Present and Future
Kilbourn, M. (2021) · Biomedicines · doi:10.3390/biomedicines9020108 · Cited by 17
“The suicide inhibitors deprenyl and chlorgylline were synthesized in carbon-11 form and demonstrated to be trapped in human brain in proportion to MAO levels, with [11C]deprenyl showing MAO-B selectivity and [11C]chlorgylline MAO-A selectivity [70].”
BackgroundKrysiak, J. M., Kreuzer, J., Macheroux, P., Hermetter, A., Sieber, S. A., & Breinbauer, R. (2012) · Angewandte Chemie · doi:10.1002/ange.201201955 · Cited by 20 · see citing works
Simplifications in analyzing positron emission tomography data: effects on outcome measures
Logan, J., Alexoff, D. L., & Kriplani, A. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.003 · Cited by 14 · see citing works
Self-citationKarmakar, A., Maitra, S., Chakraborti, B., Verma, D., Sinha, S., Mohanakumar, K. P., Rajamma, U., & Mukhopadhyay, K. (2016) · BMC Genetics · doi:10.1186/s12863-016-0401-6 · Cited by 11 · see citing works
“MAOB activity in human increases with age [22] and is selectively inhibited by low concentration of deprenyl; but in high concentration, the selectivity is lost [23].”
BackgroundNag, S., Jia, Z., Svedberg, M., Jackson, A., Ahmad, R., Luthra, S., Varnäs, K., Farde, L., & Halldin, C. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00631 · Cited by 9
Thordardottir, S., & Graff, C. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179922 · Cited by 9 · see citing works
Biomarkers for Alzheimer’s Disease Drug Development
Perneczky, R. (2018) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7704-8 · Cited by 8
Newly Synthesized Fluorinated Cinnamylpiperazines Possessing Low In Vitro MAO-B Binding
Jevtić, I., Lai, T., Penjišević, J. Z., Dukic-Stefanovic, S., Andrić, D., Brust, P., Kostić-Rajačić, S., & Teodoro, R. (2020) · Molecules · doi:10.3390/molecules25214941 · Cited by 5
“To track the efficacy of these MAO-B tailored therapies and also to monitor the changes in the receptor availability during disease progression, attempts to develop positron emission tomography (PET) imaging agents were also extensively explored (Figure 1) [13,14].”
BackgroundFluorescent Probes for Analysis and Imaging of Monoamine Oxidase Activity
Kim, D., Jun, Y., & Ahn, K. (2014) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2014.35.5.1269 · Cited by 5 · see citing works
In vitro and in vivo imaging of Phase I xenobiotic-metabolizing enzymes
Yoon, S. A., Cha, Y.-R., Fortibui, M. M., Yoo, S. Y., Jo, E.-Y., Kang, C., & Lee, M.-H. (2023) · Coordination chemistry reviews · doi:10.1016/j.ccr.2023.215248 · Cited by 5 · see citing works
PET and the multitracer concept in the study of neurodegenerative diseases
Engler, H., Damián, A., & Bentancourt, C. (2015) · Dementia & Neuropsychologia · doi:10.1590/1980-57642015dn94000343 · Cited by 4 · see citing works
Linnman, C., & Borsook, D. (2013) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10133 · Cited by 4 · see citing works
Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery
Mercier, J., Provins, L., & Hannestad, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12437-0 · Cited by 4 · see citing works
Hu, Y.-H., Zhao, Z.-T., Ma, Y., He, X.-L., & Shi, C.-H. (2025) · Biochimica et biophysica acta. Reviews on cancer · doi:10.1016/j.bbcan.2025.189506 · Cited by 3 · see citing works
An efficient preparation of labelling precursor of [11C]L-deprenyl-D2 and automated radiosynthesis
Zirbesegger, K., Buccino, P., Kreimerman, I., Engler, H., Porcal, W., & Savio, E. (2017) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-017-0029-5 · Cited by 3 · see citing works
“The PET tracer [11C]L-dep- renyl-D2 binds selectively and irreversibly to the MAO-B (Fowler et al. 1987; Fowler et al. 2005).”
BackgroundYates, S., Ahuja, N., Gartside, S. E., & McAllister-Williams, R. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311413497 · Cited by 3
“There is a paucity of human data regarding MAO-A turnover, although there is a report that following irreversible blockade with l-deprenyl, MAO-B recovery has a half life of around 6 weeks [Fowler et al. 2005].”
BackgroundPET Imaging of Monoamine Oxidase B
Rodriguez-Vieitez, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_15 · Cited by 3 · see citing works
Monoamines: Human Brain Imaging
Wong, D., & Gjedde, A. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.01151-7 · Cited by 3 · see citing works
Hedman, K., Jonasson, M., Appel, L., Tolf, A., Burman, J., & Lubberink, M. (2026) · Journal of Cerebral Blood Flow and Metabolism · doi:10.1177/0271678x251384264 · Cited by 2 · see citing works
“28,29 There are several reasons for favouring λ k 3 over k 3 or the more commonly used net influx rate ( K i = K 1 k 3 /(k 2 + k 3 ) ).”
Molecular neuroimaging of the serotonergic system with Positron Emission Tomography
Silberbauer, L., James, G. M., Spies, M., Michenthaler, P., Kranz, G., Kasper, S., & Lanzenberger, R. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00009-8 · Cited by 2 · see citing works
A Practical Radiosynthesis of (S)-[11C]SMBT-1 for MAO-B PET Imaging.
Akula, H. K., Pati, S., Qu, W.-C., Slifstein, M., Parsey, R. V., Harada, R., Furumoto, S., Okamura, N., Kim, M.-J., & Hu, B. (2026) · Journal of labelled compounds & radiopharmaceuticals · doi:10.1002/jlcr.70037
Kanuri, S. H., & Sirrkay, P. J. (2024) · Neurology Letters · doi:10.61186/nl.3.3.19
Lawal, I., Vorster, M., Nyakale, N., & Sathekge, M. (2020) · PET and SPECT in Psychiatry · doi:10.1007/978-3-030-57231-0_24
Stimulating Neuroprotective and Regenerative Mechanisms in Alzheimer Disease
Lilja, A. M. (2013) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.8515
“Astrogliosis can also be seen in vivo using the PET tracer 11C-deprenyl, which binds to monoamine oxidase type B predominantly localised to the outer mitochondria membrane of reactive astrocytes (Fowler et al., 2005).”
BackgroundPET Imaging as a Diagnostic Tool in Alzheimer’s Disease
Rinne, J. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_13
Annual Congress of the European Association of Nuclear Medicine
McEwan, A. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1915-9
“The MAO-A and MAO-B systems show early on alterations and, consequently, these systems can be specifically targeted with PET radioligands, including e.g. 11C-deprenyl (Fowler et al., 2005).”
- Authors
- Fowler, J. S., Logan, J., Volkow, N. D., & Wang, G.-J.
- Affiliations
- Brookhaven National Laboratory (US)
- National Institutes of Health (US)
- Corresponding author
- Fowler, Joanna S.
- Venue
- Molecular Imaging and Biology
- Published
- 2005-11
- Volume
- 7
- Issue
- 6
- Pages
- 377-387
- ISSN
- 1536-1632 (ISSN-L)
- 1860-2002
- OpenAlex
- W2025109436
- Cited by
- 81
- References
- 0
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 7 · 2019: 1 · 2018: 7 · 2017: 7 · 2016: 4 · 2015: 4 · 2014: 8 · 2013: 7 · 2012: 7
- FWCI
- 0.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Molecular Imaging and Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K05DA020001)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002630, EB2630)
- National Center for Research Resources (#M01RR10710, M01RR010710)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- monoamine oxidase, monoamine oxidase A, monoamine oxidase B, positron emission tomography, radioactive tracers, clorgyline, selegiline, carbon-11, human brain imaging, peripheral organs, neurotransmitter modulation, tyramine
- MeSH terms
- Aging, Animals, Humans, Monoamine Oxidase, Monoamine Oxidase Inhibitors, Neurons, Parkinson Disease, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
